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ABSTRACT 
RNA interference (RNAi) is a method that can be used to treat various medical conditions. This 
method can silence expression of virtually any gene, and it is initiated by small interfering RNA 
(siRNA) molecule. siRNA is a 19 nucleotides-long double stranded RNA-molecule. In order to 
begin gene silencing, siRNA needs to be delivered to the cytosol. The first of the barriers that 
stand on the path of the siRNA delivery is endocytosis. Endocytosis is a process by which 
nutrients, signals and pathogens enter the cells. This process consists of multiple pathways that 
lead the objects that were ingested by the cells to different intracellular destinations. The 
chemical environment encountered by the endocytosed objects also depends on the specific 
pathways. Because of the large size, negative charge and other chemical properties, siRNA 
cannot readily enter the cells. One of the most promising techniques to deliver siRNA is to 
employ its anionic property to electrostatically complex it with cationic lipids or polymers and 
create lipid- or polymer based particles (lipoplexes or polyplexes). The materials that are used as 
the delivery vectors can mediate the uptake and the release of siRNA in the cytosol. In order to 
synthesize newer generation of the delivery materials, it is paramount to know through which 
endocytosis pathways the current materials deliver their cargo and which limitations they 
encounter. In the study presented here, two representatives of the siRNA delivery vectors were 
chosen, and the investigation into their endocytosis in HeLa cells was performed. Chemical and 
biological (RNAi) methods were used to selectively inhibit endocytosis pathways and investigate 
the influence of inhibition on total uptake of and RNAi mediated by polyplexes and lipoplexes. 
Fluorescence microscopy was also used to determine the predominant pathways in the siRNA 
delivery by two different materials. The experiments revealed that polyplexes enter the cells 
through multiple endocytosis pathways simultaneously, and the expression of the delivered 
siRNA is the most prominent when polyplexes enter through caveolin-, flotillin- and ARF6-
mediated endocytosis pathways. ARF6 might play multiple roles in the delivery and release of 
the delivered siRNA in cells. Lipoplexes, on the other hand, enter the cells and release siRNA 
through a method of direct fusion with the plasma membrane rather than endocytosis. The data 
and conclusions presented in this study are consistent with the current knowledge and expand on 
the understanding of the complicated endocytosis mechanisms of siRNA-based particles. 
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CHAPTER 1: INTRODUCTION 
Since essentially all human diseases have a genetic component, the rapidly developing 
field of genetic engineering can provide solutions to many medical conditions. Efficient delivery 
of genetic material or oligonucleotides can either restore lost function to the cells or provide 
regulation to various functions of the cells. Several possible targets for such therapy have been 
proposed. For example, p53 is a well-known protein that is a product of the TP53 gene and is a 
target for cancer gene therapy. P53 is responsible for cell cycle regulation and arrests DNA 
replication if the DNA is damaged. Since it was discovered in 1979 TP53 was thought to be an 
oncogene, but as more and more studies were done it was reclassified into protooncogene.
1
 This 
means that the mutation of TP53 is what causes an uncontrolled division of cells. Since the 
mutation or loss of TP53 has been identified as the most common single genetic trait in many 
cancers, the restoration of its function could bring a revolutionary treatment in cancer therapy. 
Cancer is not the only field that can benefit from genetic engineering. Several targets for genetic 
engineering were identified and are currently explored in clinical trials of cardiovascular therapy. 
Patients with chronic lower limb ischemia can greatly benefit from additional vascular 
endothelial factor expression that was found to increase vasculature and reduce amputation 
rates.
2
 The delivery of genetic material that codes for nitric oxide synthase protein into porcine 
blood vessels was able to increase the synthesis of nitric oxide that can reduce negative 
postsurgical response of endothelial cells.
3
   
The restoration of the lost function of genes is not the only benefit that genetic 
engineering can provide. The discovery of a powerful regulatory mechanism of RNA 
interference (RNAi) in 1991
4
 and the discovery of one of the main mediators of this process 
(small interfering RNA) 10 years later 
5
 opened new possibilities of down regulation or almost 
complete elimination of aberrant genes. Just like the addition of genetic material, the suppression 
of expression of certain genes can provide an immense therapeutic potential. In analogy to 
previous examples, some sequences of small interfering RNA (siRNA) can induce apoptosis. A 
successful delivery strategy of such siRNA was shown to be effective in reducing tumors in vivo 
and in vitro.
6
 Restenosis is a common condition that is triggered by inflammation resulting by 
oxidative stress of patients that have undergone arterial interventions. Successfully induced 
RNAi targeting an oxidase protein in blood vessels of rats has been shown to dramatically reduce 
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restenosis without any significant side effects.
7
 This means that RNAi can be used to treat many 
of the conditions that were envisioned for the more conventional DNA-based gene therapy.  
In some cases, RNAi treatment could be easier and safer to implement than DNA-
treatment. As described later (Sec. 2.1), RNAi can be initiated by siRNA that is delivered to the 
cytosol, while in the DNA-therapy the molecule needs to be delivered to the cellular nucleus. 
This means that there are potentially less obstacles to RNAi therapy. RNAi can either be initiated 
by direct delivery of siRNA into the cytosol or by delivery of a plasmid DNA that ultimately 
codes for the siRNA production. When the first method is implemented, the response is usually 
transient, but when the second method is used, then the RNAi can be permanently induced (Sec. 
2.4).  Some researchers claim that the delivery of synthetically produced siRNA is not a viable 
option for many in vivo applications, because the effect is not long lasting enough for the 
treatment.
8
 However, recent studies indicate that permanent expression of siRNA can be highly 
toxic.
9
 So the transient therapy initiated by direct delivery of siRNA can be a much safer option. 
It can also provide for a higher degree of control over the dosage, and allow the therapist to 
adjust the amounts of delivered siRNA based on the response from the patient or even halt the 
treatment when required. In addition, when appropriate delivery methods are implemented, the 
effects of siRNA therapy were demonstrated to last for over 11 days in non-human primates.
10
  
Such options would certainly be an important factor in the approval of the procedure by 
regulatory agencies. 
Currently there are no USFDA approved gene therapy products,
11
 but many clinical trials 
for such therapies are in progress.
12,13
 The first stage III RNAi-trial involved the treatment of wet 
age-related macular degeneration. The disease is caused by excessive growth of blood vessels 
that cause detachment of the retina. The growth of the blood vessels can be limited by RNAi-
mediated inhibition of the VEGF protein. However, the trials had to be stopped as a result of 
either wrong choice of the target protein or insufficient RNAi efficiency.
14
 The company is 
currently considering the usage of delivery vectors, since their initial attempt involved the 
delivery of “naked” siRNA.13  
 The advancements in gene sequencing and analysis of large data sets have greatly 
increased our understanding of possible targets of gene delivery. Yet, this knowledge was not 
translated into practical applications mainly due to lack of vectors that are capable of delivery of 
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biological therapeutic agents into the target cells in a safe and controlled manner. The 
development of such vectors should be based on design that will emerge from better 
understanding of processes that govern the transport of the therapeutic molecules into the cells. 
One of the main barriers on route to the target destination is the uptake step. It is widely accepted 
that cells internalize particles from the surrounding through endocytosis.
15
 This process is highly 
complex and involves multiple pathways that act simultaneously. The uptake through each of the 
pathways leads to different intracellular destinations. It is paramount to have the knowledge of 
the predominant pathways and conditions that are imposed on the particles that undergo uptake 
into the cells in order to make this process more efficient and controlled.  In the study presented 
here, we have chosen two vectors that are common to gene delivery and investigated the biology 
of their uptake and subsequent processing using multiple tools.  
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CHAPTER 2: BACKGROUND 
2.1 RNAi: a post-transcriptional regulation mechanism 
RNA interference is a post transcriptional gene silencing mechanism that might be 
initiated by different means.
16
 Both the small interfering RNA (siRNA) and micro RNA 
(miRNA) can regulate gene expression by either triggering an endonuclease cleavage or by 
increase of the decapping (removal of special stabilizing nucleotide on the 5’-end) rates of 
mRNA. The two molecules present similar functions, but they are distinguished by their 
origin.
17,18
 Just like the siRNA, miRNA is a small molecule (19-22 nucleotides long). However, 
miRNA is an endogenous single stranded product of cells that is processed by Dicer from 
structures that contain a hairpin structure.
19
 siRNA is most commonly delivered to cells 
exogenously, but they can also be produced by endogenously produced or exogenously delivered 
double stranded RNAs (dsRNA). Both of these small molecules share most of the RNAi protein 
machinery. 
The specific structure of siRNA is a 19 nucleotide duplex with two-nucleotide overhangs 
on both 3’ ends (Fig. 2.1).13 One of the strands is called the passenger strand and the other is 
called the guide strand. The sequence of the guide strand is complimentary to a portion of 
mRNA sequence to be cleaved. RNAi is an ATP-dependent mechanism that requires siRNA to 
have 5’ phosphate.20 If exogenously delivered, siRNA is phosphorylated by hClp1 protein and 
can be further used in RNAi as if it were endogenous.
21
  
In human cells, the most essential and the minimal components that initiate RNAi are 
siRNA and argonaute2 protein.
22
 The combination of these two components is called an active 
RISC (RNA-induced silencing complex) that is capable of inducing cleavage of target mRNA at 
their center.
13
 One of the functions of argonaute2 protein is to unwind the dsRNA and load only 
                       
3’ 
3’ 
5’ 
5’ 
Figure 2.1: The structure of siRNA duplex 
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the antisense (guide) strand in the cytosol. Other proteins (TRBP, PACT and C3PO) also 
participate in RNAi, but their functional roles are still not completely known.
13
  
However, attempts to reconstruct the RISC machinery in vitro were proved to be 
successful,
23
 so the mechanistic biology of the process will eventually be precisely elucidated. 
The active RISC complex is known to degrade mRNAs in a highly specific manner. A single 
mismatch in the nucleotide sequence between loaded siRNA and target mRNA can reduce RNAi 
efficacy by 30% while more than one nucleotide mismatch essentially stops the process.
24
 It has 
been determined that some of the mismatches are better tolerated, and the drop in the RNAi 
efficiency after a mismatch depends on both the location of the nucleotides and nucleotides’ 
chemistry.
25
 
Because of the complexity of the RNAi and many target opportunities, the selection of 
the siRNA for specific targets is an active research topic. Several large studies were performed 
that correlate siRNA sequence with the RNAi activity in large databases
26,27
 and with complex 
thermodynamic analysis.
28
 The criteria that should be taken into account when selecting siRNA 
include the stability of the active RISC, selection of the proper strand for guidance and 
immunogenicity
29
. The selection of the passenger strand by RISC as a guide strand can not only 
reduce the efficiency of RNAi but also introduce an off-target effect. To prevent this, there is a 
need to introduce siRNA “asymmetry.”30 Asymmetry of siRNA is a quality that is based on 
thermodynamics and ensures that only the guide strand is incorporated in RISC. It is now known 
that asymmetry is enhanced when the 5’ end of the antisense strand is enriched with A-U base 
pairs
13
. The choice of targeted mRNA is also important, since various secondary structures can 
reduce the efficiency of RNAi.
31,32
 In addition, for a potential of inducing cytotoxicity due to the 
excessive hijacking of the native RNAi machinery, siRNA can also induce an inflammatory 
response due to specialized receptors that exist on the immune system cells.
13,33,34
 Statistical 
tools to predict the most suitable siRNA for the selected targets are reviewed elsewhere.
27,35
 
2.2 Delivery barriers 
As described above, one of the ways to initiate RNAi is to deliver siRNA to the cytosol. 
However, such a task is not trivial, since siRNA is a large, anionic and fragile molecule that 
cannot readily cross cellular membranes. Simple intravenous injection of “naked” siRNA is not a 
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feasible delivery option, since siRNA is attacked by RNAse and other blood proteins and is 
cleared from the system in a matter of minutes.
36–38
  The delivery barriers that are also known 
from the better explored pDNA delivery studies
39–41
 include two sets: extracellular and 
intracellular. In brief, upon the entry into a body, the delivered molecule should evade the 
immune system, survive the rheological stress (intravenous injection), recognize and attach itself 
to the cells that are the focus of the specific therapy, be internalized by the cells and, finally, be 
delivered to the intracellular destination without being degraded.  But they apply to the siRNA 
delivery only to some extent as a consequence of several reasons. First is that while it is usually 
desired to deliver pDNA to the nucleus, the siRNA has to be delivered to the cytosol. Second, the 
sizes of the DNA-particles usually differ from the ones that are formed with siRNA as a result of 
pDNA being larger molecules that can easily deform and be “condensed” by delivery vectors 
(more on them below) and siRNA behaving more like rigid-rod molecules.
42,43
 The degradation 
of the delivered molecules can also be described as a delivery barrier, and since siRNA contains 
extra hydroxyl group, compared to DNA, it is more prone to degradation by nucleases in serum 
that digest along phosphodiester backbone.
43
  As a result, there is a need for a delivery vector 
that will mediate the passage of siRNA through the barriers while keeping it intact, and release 
siRNA into the cytosol. Since eventually the materials that will mediate siRNA delivery will 
differ from the materials used for pDNA-delivery, it is natural to assume that different delivery 
barriers will be posed for these molecules.  
2.3 Biological mechanisms of endocytosis 
Endocytosis is one of the main barriers that siRNA needs to overcome before it can 
initiate a therapeutic effect. Since this complicated process is investigated by researchers from 
multiple fields, it is worthwhile to initially review it from purely biological prospective 
(discussed here) and then to review its implications on the siRNA delivery (Sec. 2.5). 
Endocytosis is a process that describes de novo production of internal membranes from 
the plasma membrane lipid bilayer.
44
 Such process is essential to all cells, since cells 
continuously use it to obtain their nutrients, exchange signals, regulate amounts of receptors and 
probe the environment. The process of the uptake of the membrane is counterbalanced with the 
recycling activity back to the plasma membrane, and it is estimated that every hour the cells can 
internalize 1 to 5 equivalents of their surface.
45
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Endocytosis consists of multiple uptake pathways. Thus, there have been several attempts 
to classify these pathways into groups; however these attempts have largely been unsuccessful, 
since not all of the pathways have already been discovered, and the research of the biology of the 
known pathways is still an ongoing topic. The separate pathways are known either by the type of 
cargo that they let cells internalize (e.g. macropinocytosis), by the proteins that are associated 
with the pathways (e.g. clathrin-mediated endocytosis) or by the proteins that are known not to 
be associated with the pathways (e.g. clathrin-independent endocytosis). The common 
characteristic of these pathways is that they form vesicles at the plasma membrane that 
invaginate into the cells. These vesicles (endosomes) have different fates that depend on the 
endocytosis pathway that promoted their formation and on their cargo.  
Macropinocytosis (MPE) is among the earliest discovered pathways
46
 and is 
characterized by the formation of large (0.2-10 µm in diameter)
47
 vesicles that are called 
macropinosomes. These vesicles are formed from the ruffling of the plasma membrane. Even 
though this pathway does not discriminate against the cargo, it has now become clear that it is 
highly regulated. The pathway is known to depend on a large number of proteins: Rac, Pak1, 
Cdc42, CtBP1/BARS, ARF6. The process is mostly driven by actin, and is usually activated by 
growth factors, however, it is also found to be highly active in cancer and immune system 
cells.
48–50
 The pathway is commonly inhibited by Na+/H+-inhibitors such as amiloride or 
derivatives of the drug; only recently it has been discovered that these inhibitors act by lowering 
submembraneous pH which leads to prevention of activation of Rac1 and Cdc42 proteins.
51
 
Amiloride is such a specific marker for MPE, that it was suggested to define this pathway as one 
that is suppressed by amiloride, stimulated by growth factor and has morphology of large 
vesicles.
48
 MPE also depends on the cholesterol content of the plasma membrane, since 
cholesterol appears to be required for the localization of Rac1 on the plasma membrane.
52
 The 
fate of the macropinosomes seems to depend on the type of the cells. For example, 
macropinosomes were found to fuse with acidic late endosomes and lysosomes in macrophages 
and kidney cells but remain separated from endolysosomal system and recycle back to plasma 
membrane in A-431 and NIH-3T3 cells. Macropinosomes are also more leaky compared to other 
types of endocytic vesicles.
48,53
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Clathrin-mediated endocytosis (CME) is one of the most studied and well described 
pathways. The term “receptor-mediated endocytosis” was synonymously used with the term 
“CME” for a very long time. It is such an important pathway, that it is expected that around half 
of the internalization by fibroblastic cells is done through CME,
44
 and many of the contemporary 
review articles are concentrated on clathrin-independent pathways as opposed to CME. The 
formation of clathrin cage around the invaginations at the plasma membrane was first 
demonstrated and confirmed in 1996.
54
 This cage is characteristic to this pathway, but its 
formation is only one of the five main steps in CME that were exhaustively reviewed recently.
55
 
First, a putative nucleation module that contains FCHO proteins, EGFR-pathway substrate and 
intersectins is formed on the plasma membrane. Highly conserved adapter 2 (AP2) proteins 
along with other numerous cargo-specific adapter proteins are then recruited. A wide range of 
these adapter proteins along with different receptors have been identified in various cells. These 
proteins also give CME the ability to endocytose multiple different cargoes. The various adapter 
proteins always bind to the AP2, and AP2 then recruits clathrin triscelia directly from cytosol 
while simultaneously binding to the cargo. Since clathrin binds to a flexible region of adapter 
proteins, it has been thought that some other membrane curvature effectors are required in order 
to create a pit in the plasma membrane. The mechanochemical enzyme called dynamin 
undergoes GTP hydrolysis-driven conformational change at the “neck” of the formed vesicle, 
and the vesicle is cut from the plasma membrane. The location on the vesicle where it buds off 
the membrane remains not covered with clathrin cage, and it is hypothesized that two proteins 
(HSC70 and auxilin) disassemble the clathrin cage starting at that location shortly after the 
budding event.
55
 Scores of different adapter proteins have been identified in the CME. These 
proteins can recruit various receptors allowing CME to be one of the most versatile pathways. 
Caveolin-mediated endocytosis (CvME) originates from flask like structures of 50-100 
nm on the plasma membranes that are thought to be associated with lipid rafts. Such structures 
are named caveolae and have a coat that contains 100-200 caveolin-1 proteins per caveola.
44
 
Caveolin-1 proteins assemble on the plasma membrane by direct binding to cholesterol. The 
caveolar pathway is associated with the uptake of multiple ligands that include albumin, 
autocrine motility factor, tetanus toxin, cholera toxin and multiple types of viruses.
49
 The 
invagination of caveolae that forms vesicles termed caveosomes is poorly understood and is a 
subject to controversy.
50
  Electron microscopy of fixed structures and fluorescence microscopy 
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revealed that caveolae structures on plasma membranes are immobilized and do not enter the 
cytosol. They form long tubular structures that go deep inside the cells, and caveolin-1 structures 
are generally very stable.
56
 Calls have even been made to abandon the term “caveosome,” and 
significant evidence suggests that caveosomes are actually late endosomes that contain large 
amounts of caveolin-1 proteins “awaiting degradation.”57 Other investigations revealed caveolin-
1-positive structures bud from the plasma membrane, but these events are very rare.
58
 
Nevertheless, caveolin-1 protein is found to be associated with other less known pathways such 
as CLIC/GEEC (more on it below), and the investigation of CvME can lead to important 
discoveries.
44
 It is important to note that it is widely accepted that endosomes that are associated 
with CvME are not acidified and travel to Golgi and/or ER as opposed to endosomes that are 
associated with CME that rapidly acidify and degrade their cargo in lysosomes.
59,60
 
Flotillin-mediated endocytosis (FME) is a relatively novel pathway that has yet to be 
explored in depth. Flotillin-1 is a protein that is homologous to caveolin-1
44
, however it was 
found in plasma membrane domains distinct from caveolae and thought to form a major pathway 
in mammalian cells.
61
 Flotillin-1 was found to be necessary for dynamin-dependent but caveolin-
1 and chlathrin-independent uptake of negatively charged plasma membrane proteoglycans that 
end up in late endosomes in HeLa cells.
62
  The FME pathway may be also responsible for fluid-
phase uptake in HeLa cells, since many flotillin-positive structures were found to be co-localized 
with dextran (a fluid phase marker) that is also used for MPE investigations.
49,61
 
ARF6-dependent endocytosis is a pathway that is associated with formed vesicles that 
contain ARF6 protein.
44
 ARF6 is one of the many members of the ADP ribosylation factor 
family of GTP-binding proteins that has multiple roles including influence on membrane 
trafficking, actin skeleton structure at plasma membrane, and membrane lipid modification.
63
 
ARF6 can act as a regulator of recycling to the plasma membranes
44
 or as a protein that is 
directly involved in endocytosis, since it was found to be characteristic to endosomes that are 
clathrin and dynamin- independent and separate from CLIC/GEEC structures. Because these 
endosomes appear to communicate with transferrin-containing vesicles that are associated with 
CME, the role of ARF6 that is also contained in specialized tubular recycling membranes
44,49,63
 
in endocytosis is difficult to investigate. Significant evidence suggests that at least in some cell 
types ARF6 acts more as a CME regulator than an independent pathway regulator. Specifically, 
ARF6 interacts with AP2 in HeLa cells and promotes clathrin recruitment and regulates uptake 
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of G-protein coupled receptors by CME in HEK293 cells.
56
 ARF6 can either be directly involved 
in formation of endosomes or be incorporated later in the recycling step.
49
 The list of cargo that 
can be internalized through an ARF6-dependent pathway include β1-integrin, M2 muscarinic 
receptor and some GPI-anchored proteins. The vesicles formed from ARF6 uptake fuse with 
early endosomes and traffic to lysosomes or recycle to plasma membrane through tubular 
structures.
41
 Reduction of ARF6 content in retinal pigment epithelial cells (ARPE-19) using 
RNAi inhibited the uptake of MPE markers and did not alter the uptake of transferrin (CME 
marker) indicating the importance of ARF6 in MPE.
64
  Only the active form of ARF6 (ARF6-
GDP) is required for the recycling pathway; the inactive ARF6 (ARF6-GTP) is associated with 
direct endocytosis.
45
  
Aside from other endocytosis pathways that are characteristic to specialized cells (e.g. 
phagocytosis by phagocytes) there exist several other pathways associated with complex 
biological mechanisms that are still not completely clear. CLIC/GEEC pathway characterizes 
clathrin- and dynamin- independent endosomal compartments enriched with GPI-AP proteins 
that do not have cytosolic extentions.
49
 The vesicles that are formed in this pathway are tubular 
in their shape, form special early endosomal compartments and do not travel to Golgi. 
CLIC/GEEC is responsible for fluid-phase uptake, and it is heavily dependent on cholesterol.
65,66
  
Another example of such a pathway is characterized by the tetraspanin CD58-enriched domains. 
This pathway is not dependent on clathrin, caveolin, flotillin or dynamin; it is also not disturbed 
by cholesterol depletion and is similar to the GEEC pathway.
49,67,68
 Several other pathways exist, 
but their biological mechanisms have yet to be determined.
49
 
The vesicles that are formed in these different endocytosis processes have different 
surfaces, lumina and physico-chemical properties that allow them to process the cargo in various 
ways. After uptake, the vesicles that formed from many of the pathways are sorted and delivered 
to different intracellular destinations. 
69
 The elucidation of the sorting and delivery of the 
vesicles is still not clear. However it is evident that the formed vesicles preserve the “memory” 
of their origin using protein or lipid markers.
55
 This is because although most of the vesicles 
formed from the above described pathways become early endosomes
15
, these endosomes are 
destined for different intracellular destinations. The traffic of endosomes and the exit from them 
are termed “retrograde transport” and “retrograde sorting.”70 Numerous molecules on the 
endosomes are known to act as keys for locks that are located on various intracellular 
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destinations such as Golgi, ER, and lysosome. These tethering proteins in turn serve as 
connectors between Rab and SNARE proteins.
15
 Rab-family proteins consist of over 60 
molecules that act as switches in the intracellular processes. They are implicated in un-coating 
and movement of vesicles, and fusion between endosomes and their recipients. For example, 
Rab5 is implicated in movement of clathrin-coated vesicles into early endosomes, while Rab9 
with late endosome to Golgi; Rab25 is a marker of recycling endosomes destined for exocytosis. 
One of the most complete reviews of Rab GTPases was published by Stenmark in 2009.
71
 It is 
important to study the intracellular trafficking because the design of the delivery vectors should 
be based on the conditions that the vectors experience during the delivery process. Also, the 
design of the delivery vector can influence the endocytosis pathway that the particles will use to 
enter the cells and reach their ultimate destination. 
 
 
2.4 Delivery vectors 
As a result of the delivery barriers that were described above, there is a need for siRNA 
vectors capable of assisting siRNA to initiate RNAi There are two main classes of vectors that 
are employed in gene delivery. Viruses are most commonly used for the delivery of genetic 
material. They are much more efficient than other vectors and are employed in many of the 
clinical trials. Three important types of viruses that are used include adenoviruses, adeno-
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lots of biology is yet to be explored 
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associated viruses and retroviruses.
13
 The first two types can deliver DNA, and some 
modifications to the adeno-associated viruses can make them very promising in long-term 
treatments.
72
 However, retroviruses are more commonly used, deliver RNA, and use integration 
to incorporate their code in host’s genome. The main benefit of viruses is that they are capable of 
inducing long term expressions. Viruses have been evolving for millions of years, which made 
them very efficient but also well recognized by mammalian immune systems. Many of them are 
immunogenic and as a result were fatal in clinical trials.
73,74
 It is believed that RNAi was 
developed in order to provide protection of cells from expression of foreign (viral) RNA.
5
 Viral 
therapy can also induce cancer, mainly because of inability to control the location where the viral 
DNA is integrated.
75
 As for RNAi, viruses can be used to efficiently integrate shRNA expression 
cassettes. In fact, such treatment proved to be fatal to mice due to oversaturation of RNAi 
pathway caused by overexpression of shRNA delivered using adeno-associated virus.
9
 As a 
result of all the drawbacks with viral vectors, there is a need in development of alternative means 
of delivery. 
Non-viral delivery systems are well known from the more mature DNA-delivery 
research.
39,41,76
 The ideal requirement for these vectors is to deliver the material to the target cell 
nucleus through all of barriers without having any of the drawbacks of the viral systems. 
Fortunately, at least two classes of materials are known to be able to electrostatically bind to the 
DNA or siRNA and successfully mediate the delivery. These materials include lipids and 
polymers. 
Cationic lipids are known to bind siRNA or pDNA and form particles that are called 
lipoplexes. The first published study to utilize a synthetic cationic lipid for gene delivery was 
published in 1987.
77
 N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
(DOTMA) was used to deliver DNA in vitro. Since then DOTMA was also used in mRNA and 
siRNA delivery.
78,79
 Next generation of now commonly used lipid was N-[1-(2,3-
Dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP) (Fig. 2.3).
80
 More 
recently, a large library of 700 cationic lipids was assembled to investigate the relationship 
between their structure and ability to mediate RNAi in siRNA delivery.
81
 Their conclusion was 
that lipids that contain more than two amines per head unit, and two long or several small amide 
tails were the most effective. Based on their earlier data, they synthesized another lipid library 
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that was tested on HeLa, and the best performing lipids contained amide linkages, more than two 
alkyl tails, tail in range of 8-12 carbons and one tail short of total substitution of the amine 
reactants. In addition to using single lipid as a vector, some studies demonstrate that a mixture of 
different lipids can be used to significantly enhance transfections. For example, in in vitro 
pDNA-delivery study using DOTAP no transfections could be achieved when the serum levels 
were up to 80%, but the addition of cholesterol improved the cell binding and uptake 
mechanisms to significant levels.
82
 Other studies demonstrated the importance of incorporating 
cholesterol as a helper lipid in vivo.
83,84
 
85
 
Dioleoylphosphatidylethanolamine (DOPE) is another helper lipid (Fig. 2.3) that is used 
to promote delivery.
8484,86
 It is hypothesized that DOPE facilitates the release of the delivered 
material by changing its phase from bilayer to hexagonal structure.
87
 DOPE can also help in 
disassembly of the nucleic acid-particle once the particle is inside of the cell, all of which may be 
a result of the pH-sensitivity of DOPE.
84,86
  The research presented here employed the properties 
of the above presented lipids in construction of a delivery reagent that consists of DOPE, 
DOTAP and cholesterol that was optimized for siRNA delivery. Because of the popularity of 
these materials, the constructed vector will act as a typical representative of the entire class of the 
lipid vectors. 
 Cationic polymers are another class of materials that can electrostatically bind negatively 
charged siRNA or DNA and act as delivery agents.
79
  The common feature of many of these 
polymers is their ability to self-assemble into nanoparticles when mixed with DNA or siRNA in 
solutions. Such particles are often called polyplexes. Examples of these materials include 
Polyethylenimine (PEI), chitosan, and dendrimers such as poly(amidoamine) (PAMAM). Just 
like with lipids, most of these polymers were initially used for DNA-delivery and now have been 
explored for RNAi applications. PAMAM are dendrimers that have primary amine groups on 
their surface and tertiary amine groups inside of their structures. Not only have they been used 
for successful DNA delivery
88
, but it has been shown that their partial degradation can lead to 
significant increase in their efficiency.
89
 A study was performed that investigated the binding of 
siRNA to different generations of PAMAM using computational approach that was 
experimentally verified.
90
 The study found that lower generations (G4) of PAMAM adapt better 
to siRNA, while higher generations (G6) act more like “rigid spheres.” Interestingly, the studies 
that characterized PAMAM as a siRNA delivery agent in vitro found higher generations of 
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PAMAM to be more efficient in inducing RNAi than lower generations.
91,92
 This might provide 
an insight in the relationship between the structure and the function of the polymers.  
PEI is one of the best studied delivery vectors.
39,76,79
 It is one of the “off the shelf” 
polymers that is highly efficient in both DNA and siRNA deliveries. Every third atom in the PEI 
backbone is a protonatable nitrogen (Fig. 2.3A). PEI has a high charge density and can bind to 
siRNA well. In addition, this gives PEI a high buffering capacity that facilitates the escape from 
the subcellular endosomes that is explained as a “protone-sponge” mechanism93,94 (discussed 
below). Unfortunately, PEI is too toxic to be used as a therapeutic agent, even though it has been 
used successfully in some in vivo studies.
95
 It causes toxicity in two stages by disrupting plasma 
membrane and initiating mitochondrially mediated apoptotic program in human cell lines.
96
 PEI 
is commercially available at a very wide range of molecular weights. It has been extensively 
modified by changing core structure and addition of various targeting molecules.
79
 As an siRNA 
delivery agent, PEI could protect the delivered siRNA cargo in mice and mediated cancer 
treatment.
97
 Because of its wide usage and great potential, we have chosen to further investigate 
its properties as a model cationic delivery polymer in the study presented here. 
 Overall, the presently explored non-viral delivery agents cannot compete with the 
efficiency of the viral vectors. However, once the mechanisms by which they mediate RNAi will 
be fully explored, the road for the synthesis of novel materials that will be at least as efficient as 
the viruses without most of the drawbacks will be open.  
15 
 
  
2.5 Endocytosis in the context of siRNA delivery 
The ultimate goal of a siRNA delivery vector is to release siRNA molecules in the 
cytosol. After uptake into the cells, siRNA release could be accomplished in several locations. 
Juliano et al. predicted some of these locations.
15
 It is presumed that to gain access to cytosol, the 
particles need to enter the trans-Golgi just like many viruses and pathogens operate. However, 
this might not be an important step in the siRNA delivery, and there is no need for precisely 
addressed delivery in RNAi. As the endosomes travel through the cells they constantly fuse with 
each other and with other lipid-based membranes. Early endosomes mature to late endosomes, 
late endosomes bud small vesicles for recycling back to plasma membrane, and fusion with 
lysosomes is also common.
45
 The fusion events include the formation of non-bilayer domains 
that are inherently leakier than the bilayer domains.
98,99
 This means that the relationship between 
the induced RNAi and leakage from the endomembrane compartments can be established.
15
  
A more conventional mechanism that is hypothesized to release the delivered particles 
from endosomes is called the “proton sponge” hypothesis. As the endosomes mature, their 
internal environment becomes more and more acidic by the action of ATPases. If the internal 
space of the endosome is buffered, then the counterions that enter the vesicle together with 
protons can cause the endosome to swell and eventually rupture, releasing the contents into 
Figure 2.3: The materials that were used in the study. A. DOTAP is a cationic lipid capable of binding to 
anionic backbone of DNA or siRNA and promote the uptake. B. DOPE is a zwiterionic lipid that helps with 
the escape from the endosomes. C. Cholesterol helps stabilize the particle solution improve uptake to the 
cells. D. Branched PEI is a cationic polymer that was used as a model for the class of such materials in 
siRNA delivery. 
A 
B 
D 
C 
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cytosol. Such delivery strategy relies on the buffering capacity of the delivery vector, and 
cationic polymers such as PEI are known to provide that.
39
 
Two investigations into the endocytosis of oligonucleotides-based particles revealed 
interesting facts. Lu and coworkers used a commercially available lipid-based siRNA 
transfection reagent (DharmaFECT1) in various cell lines and determined that although 95% of 
particles enter cells through endocytosis, the inhibition of CME, CvME, MPE and lipid-raft 
mediated endocytosis did not lead to reduction in RNAi. The depletion of cholesterol from the 
plasma membrane did not alter the uptake of the lipoplexes, but the functional delivery was 
reduced. Low temperatures during transfections also inhibited RNAi. The authors concluded that 
a new mechanism of direct fusion between the lipoplexes and plasma membranes is likely to be 
responsible for functional siRNA delivery.
100
 Another study investigated intracellular trafficking 
of antisense oligonucleotide that only expressed when delivered to nucleus (splice shifting 
oligonucleotide) using two commercially available delivery reagents: jetPEI (derivative of linear 
PEI) and Lipofectamine2k (combination of DOSPA and DOPE). They concluded that the 
functional delivery using lipid-based system occurred through direct fusion with plasma 
membrane, and PEI-based delivery happened through a dynamin and caveolin-independent 
pathway that is also not CME.
101
 Both of the studies discussed the possibilities of new 
endocytosis pathways that can mediate siRNA-delivery that were not active in the DNA-
delivery. 
2.6 Methods and tools to investigate endocytosis 
 The methods to study the endocytosis of particles can roughly be divided into three 
categories. The first is the most direct method where either the delivered cargo or the vector (or 
both) are tagged with a fluorescent marker. The particles are then delivered to cells together with 
various markers (e.g. dextran for fluid uptake or LysoTracker (Molecular Probes) for 
lysosomes). It is also common to fix the cells after the delivery and perform immunofluorescent 
staining of proteins of interest. The visualization can be done by confocal microscopy, and co-
localization (or its lack) between the delivered particles and stained molecules can directly hint 
on the intracellular fate of the particles.
102
 The drawback of this method could be the 
incorporation of small amounts of proteins into vesicles that are involved in pathways that are 
not directly associated with them. Also, the stained proteins might not even be inside of the 
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vesicles but be shuttled from the locations where they were manufactured or be recruited for 
other functions. This might lead to false conclusions when reviewing the co-localization data. 
 The second set of methods includes various genetic modifications of the investigated 
cells. The cells can be modified to express a non-functional protein that will interfere with one of 
the pathways. For example, cells that express mutant dynamin can be compared with cells that 
express regular dynamin to investigate the uptake and the efficient transfection pathways that 
involve dynamin. Similar modifications can be done with caveolin and other proteins.
101
 RNAi 
can also be used as an investigative tool. The proteins that mediate endocytosis pathways can be 
knocked out in a highly specific way. Recently, FME was implicated in polyplex delivery of 
DNA. Other tools could not be used, since there are no known markers for FME.
64
 Our group 
also used RNAi in the past to determine that CvME is the predominant pathway in PEI/DNA 
delivery in HeLa cells.
103
 Using cells that permanently express mutant proteins might not be as 
good of a method as using RNAi, since the mutant protein can affect other functions of the cells, 
while transient effect of RNAi might have fewer side effects. Since siRNA should be delivered 
with a vector to induce RNAi, it is also possible that the vector that is used will mildly influence 
the biology of the cell. Some other possible non-specific effects of siRNA were discussed above. 
 The third set of methods involves the chemical inhibitors that are commonly used to 
selectively block one of the pathways.
53,104
 The usage of drugs is the most popular method of 
studying endocytosis pathways, however this method has the biggest number of drawbacks and 
should be very carefully applied. 
105
 The in vitro protocol of using the drugs usually involves a 
short (up to an hour) pre-incubation of drugs in well plates with cells prior to transfections. Then 
the solution of transfecting particles is added to the cells, and the transfection occurs in the 
presence of the drugs. The media is then changed at the end of the transfection to a usual culture 
media. However, the drugs that are commonly used to disrupt a specific pathway are not as 
specific as usually claimed. For example, methyl-β-cyclodextrin (mβCD) is routinely used to 
inhibit CvME by depleting plasma membranes of cholesterol.
53,106
 However, as was described 
before, cholesterol is an essential component of ME and FME. In a paper published in 1998 it 
was shown that the extraction of cholesterol by mβCD can also inhibit CME by perturbation of 
the formation of clathrin-coated vesicles.
107
 Another example is a commonly used cationic 
amphiphilic drug chlorpromazine that is used as a CME inhibitor by preventing the dissociation 
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of clathrin lattice
53
 by relocating the clathrin and AP2 from the surface to vesicles inside of the 
cells.
108
 In agreement with our findings (Table 4.1) chlorpromazine was found to be very toxic at 
concentrations that are routinely used to inhibit CME, and this toxicity is cell-dependent.
105
 It 
can also incorporate itself into the plasma membrane and severely affect fluidity of the 
membrane.
109
 This in turn can alter pathways that involve the uptake of large particles like MPE. 
Chlorpromazine can also interfere with the dynamics of actin by altering the function of 
phospholipase C.
104
  
Other examples of commonly used drugs that are used in the study presented here include 
amantadine, genistein and amiloride. The function of amiloride was discussed above. Genistein 
is a tyrosine kinase inhibitor that causes local disruption of the actin network and can inhibit the 
recruitment of dynamin to plasma membranes.
53,105
 But dynamin is also essential for the scission 
and budding of clathrin vesicles. Amantadine was found to stabilize clathrin-coated vesicles and 
block their budding of plasma membrane.
103,110
  But the action of amantadine has mostly been 
evaluated on the basis of endocytosis of viruses, so there is no certainty that it does not have non-
specific action in non-viral vectors. There is also a concern that the chemical inhibitors might not 
only affect the endocytosis events but other cellular functions.
105
 Chemical inhibitors also 
demonstrate various degree of specificity amongst different cell lines and conditions. Therefore, 
special considerations of selection of these inhibitors and their concentrations should be taken. 
 Since most of the methods to study endocytosis have their advantages and weaknesses, it 
is imperative to combine such methods in studies instead of heavily relying on a single one. In 
the study presented here, we used a set of concentrations of chemical inhibitors instead of relying 
on a single concentration. We also implemented control groups that helped to reduce non-
specific action of the employed drugs and non-specificities that are associated with the toxicity 
of siRNA and the vectors themselves.  
 In conclusion, RNAi has a high therapeutic potential. The main obstacle to such therapy 
is an inability to safely deliver siRNA through the delivery barriers. One of the main barriers 
posed to delivered siRNA molecules is uptake into and subsequent processing inside of the cells. 
This highly complicated process can be subdivided into many separate pathways that have some 
overlaps but present different chemical environments to the delivered molecules. In order to 
rationally design a vector that will deliver siRNA, it is paramount to have more information on 
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the predominant uptake pathways that can lead to effective RNAi. Through the use of multiple 
chemical and biological methods we conducted an investigation into the mechanisms of the 
uptake and RNAi of two different model vectors in one model cancer cell line.  
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Cells 
HeLaLuc (luciferase-producing cervical cancer) cells were a kind gift from Mark Davis 
group at CalTech. The culture media consisted of DMEM with 10% (v/v) FBS (Gemini Bio-
Products, West Sacramento, CA), and the cells were incubated at 37°C and 5%CO2. The cells 
were cultured according to ATCC protocol except of no antibiotics or fungicides were used. 
3.2 Cytotoxicity 
The cytotoxicity of the chemical inhibitors was used as one of the factors in determining 
the concentration range of drugs that was used in this study. The cytotoxicity was measured 
using CellTiter-Blue cell viability assay (Promega, Madison, WI) according to manufacturer’s 
instructions. Briefly, cells were seeded at a density of 1X10
4
 in 96-well plates. Twenty four 
hours later, the media was aspirated and 100µl of serum-free media was added. In addition, 
drugs at various concentrations were added to the cells (n=4) and allowed to incubate for 4 
hours. The drug-containing media was then replaced with culture media, and the cells were 
placed in the incubator for 20 hours. The CellTiter-Blue reagent was then added to wells at the 
amount of 20µl/well, and the cells were incubated for 4hours. The 96-well plates were then 
placed in SpectraMAX 340 microplate reader (Molecular Devices, Sannyvale, CA) to measure 
the light absorbance at 570 and 600nm. The absorbance values at 600nm were subtracted from 
the values at 570nm, and the viability values were normalized to no-drug controls. 
3.3 siRNA 
 siRNA was used to study the efficiency of transfection, uptake of particles and in 
production of modified cells. The sequences of siRNA are presented in Table 3.1. The anti-
luciferase siRNA duplex (siGL3) and human Lamin A/C siRNA duplex (siLam) were purchased 
from Dharmacon (Lafayette, CO). Fluorescently tagged (3’-AlexaFlour647) siGL3 and the 
siRNAs that target Clathrin, Caveolin-1, Flotillin-1 and ARF6 proteins were purchased from 
Qiagen (Germantown, MD). 
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Table 3.1 Description of the siRNA used in the study 
siRNA Abbreviation Target Protein Sense Sequence 
siGL3 Luciferase 5’-CUUACGCUGAGUACUUCGATT-3’ 
siLam Lamin 5’-CTGGACTTCCAGAAGAACATT-3’ 
siCLT Clathrin, heavy chain 5’-AUCCAAUUCGAAGACCAAUTT-3’ 
siCav Caveolin-1 5’-GCAAGUGUACGACGCGCACTT-3’ 
siFLT Flotillin-1 5’-CAGAUCCAGAGGAUCUCUCTT-3’ 
siARF ARF6 5’-ACGUGGAGACGGUGACUUATT-3’ 
 
3.4 Lipids 
 A combination of three lipids was used in order to create lipid-based delivery vector. 
DOTAP, DOPE and cholesterol were purchased from Avanti (Alabaster, AL). The optimal 
composition of lipids for siRNA delivery was experimentally determined by performing 
transfections at a set of DOTAP:DOPE:cholesterol ratios of 1:0:0, 1:1:0, 1:0:1, 2:11:7, 5:8:7, 
11:2:7, 1:2:7, 3:3:14 and 2:1:7 (w:w) at 1:1 and 10:1 (w:w) of vector:siRNA ratios. The lipids 
were first separately dissolved in chloroform at concentration of 10mg/ml and mixed in glass 
tubes. The mixtures were let dry under vacuum overnight. On the next day, the lipid layer that 
formed on the bottom of the glass tubes was suspended in PIPES buffer (20mM PIPES, 150mM 
NaCl in water) at concentration of 0.2mg/ml using water-bath sonicator. The lipid solutions were 
extruded through a 100nm polycarbonate membrane 11 times using Mini-Extruder (Avanti) prior 
to being combined with siRNA. The stock of lipid-solution was kept at 4°C. 
3.5 Polymer 
 PEI was used as a model for cationic polymer for siRNA delivery. Branched 25kDa PEI 
was purchased from Sigma and suspended in ddwater at concentration of 1mg/ml. The stock was 
kept at room temperature prior to being used as a delivery vector. 
 
22 
 
3.6 Formation of Polyplexes and Lipoplexes 
 To prepare polyplexes and lipoplexes, an appropriate amount of the 20µM stock siRNA 
in RNase-free water solution was first added to PIPES buffer. The solution of lipids or PEI was 
then added to the siRNA solution to give the final weight ratio of 10:1 (vector:siRNA). The 
particles were allowed to form via electrostatic interactions at room temperature for 30 minutes 
prior to being used for transfections.  
3.7 siRNA transfection 
 HeLaLuc cells were used as a model cell line in evaluation of the uptake of siRNA 
particles and their RNAi efficiency. The cells were seeded in 12-well plates at density of 1X10
5
 
cells/well 24 hours prior to transfections.  The culture media was replaced by a 1ml of serum-
free media, and 50 µl of the siRNA-particles solution was added to each well to achieve final 
concentration of 5 nM of siRNA. The transfection media was replaced by a culture media 4 
hours later. Twenty hours after the transfection, the cells were washed once with PBS and 100 µl 
of cell culture lysis reagent (CCLR) were added to each well. Twenty microliters of each sample 
were used to evaluate luciferase expression using Promega luciferase assay (Promega, Madison, 
WI) and Lumat LB 9507 luminometer (Berthold, Oak Ridge, TN) using manufacturer’s 
instructions. The total protein content was evaluated for each sample using Pierce BCA assay 
(Peirce, Rockford, IL) and used to normalize the relative light units (RLU) that represented the 
luciferase content of each sample.  
3.8 Flow cytometry experiments to measure total uptake of particles 
 Flow cytometry was used to evaluate the uptake of the siRNA-particles. As before, the 
cells were seeded 24 hours before the transfection on 12-well plates at density of 1X10
5
 
cells/well. The particles were formed as described in Methods 3.6, but fluorescently labeled (AF-
647) siGL3was used. The cells were transfected in serum-free media for 2 hours. The cells were 
then washed once with 1ml of 0.001% SDS in PBS and once with 1mL of PBS solutions to 
remove fluorescently labeled particles on the surface of the cells. Following the washing, 200µl 
of 0.25% trypsin in PBS solution were added to each well, and the plates were allowed to 
incubate for 5 minutes. The cellular suspensions were mixed by pipetting and added to 300µl of 
FBS. The cells were stored on ice prior to be analyzed. FACS analyses were done on BD 
23 
 
FACSCanto flow cytometer (BD Biosciences, San Jose, CA), and the data was analyzed using 
FCS Express v.3.0 software (De No Software, Los Angeles, CA). The gate was set based on the 
forward and side scattering parameters of living cells, and at least 2000 cells were collected in 
each group. 
3.9 Transfections in the presence of chemical inhibitors 
 The chemical inhibitors were used to block one of the endocytosis pathways. The stock 
solutions of chlorpromazine, amiloride, amantadine and mβCD (Roquette, Gurnee, IL) were 
prepared in water at concentrations of 5, 5, 50 and 250mg/ml, respectively. The stock of 
genistein was prepared in 50mg/ml in DMSO. Prior to transfections, the stock solutions were 
mixed with water such that adding 10µl of the new drug solution to 1ml of DMEM in the wells 
would achieve the desired final concentration of drugs. All of the drugs were added to cells at 
least 30 minutes before the siRNA solutions. 
3.10 Production of RNAi-modified Cells 
 We evaluated the uptake and the RNAi effects of siRNA-particles in cells that had a 
transient selective knockdown of traffic proteins. In order to produce the modified cells (siMod 
cells), we seeded 2X10
5
 HeLaLuc cells in 6-well plates. Twenty four hours after the seeding, the 
cells were transfected in a serum-free media using RNAiMAX Lipofectamine reagent (Life 
Technologies, Carlsbad, CA) with final concentration of siRNA of 20nM listed in Table 3.1 
using the manufacturer’s protocol. Briefly, for each experimental group, we first added 
appropriate amount of siRNA to 150µl of OptiMEM (Invitrogen) and separately added 3.5µl of 
RNAiMAX to a separate container with 150 µl of OptiMEM. The solutions were incubated for 
10minutes, and the RNAiMAX solution was added drop wise to the siRNA solutions. The 
formed complexes were left at room temperature for 15 minutes and added to 2ml of DMEM that 
was placed instead of the culture media into the wells prior to transfections. Following 4 hours, 
the media was replaced with the serum-containing media and the cells were placed in the 
incubator for 24 hours. One of the control groups served a well into wich no siRNA was added 
and the other control had 20 nM siLam that does not interfere with cellular trafficking. A similar 
transfection was repeated, but at its conclusion, the cells were washed with PBS, trypsinized with 
320µl of trypsin (Cellgro, Manassas, VA) and equally partitioned into 6 wells of 12-well plate. 
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The plates were placed in incubator and cultured for 20 hours. Subsequently, the cells were 
either used in farther transfections or validated for a successful knockdown of traffic proteins 
using Western Blotting.  
 The Western Blotting of modified cells was done using Westernbreeze Chromogenic Kit 
(Invitrogen) following the manufacture’s protocol. First the samples were lysed using 300 µl of 
the RIPA Lysis Buffer System (Santa Cruz Biotechnology, Santa Cruz ,CA) and the total protein 
concentration was verified to be the same across all the samples using BCA assay. Then 10 µl of 
the sample were added to the NuPAGE (Invitrogen) buffer and reduced by adding NuPAGE 
Reducing Agent (Invitrogen) and heating the samples at 70°C for 10 minutes. The samples were 
then resolved using electrophoresis on 10% Novex Bis-Tris gels (Invitrogent) along with a 
ColorPlus  pre-stained protein ladder (BioLabs, Ipswich, MA). The proteins were transferred to 
nitrocellulose membranes, blocked with proprietary protein solutions (Invitrogen) for half an 
hour, incubated  for 1.5 hours with primary antibodies (Table 3.2), incubated with secondary 
antibodies for an hour and developed using chromogenic substrate. The membranes were then 
wrapped with plastic wrap and scanned using a desktop scanner.  
 
 
 
Table 3.2 Final concentrations of primary antibodies 
Primary Antibody Concentration Used in 
Western Blotting 
(µg/ml ) 
Concentration 
Used in Confocal 
Imaging (µg/ml ) 
Supplier 
Clathrin HC 0.4 6 Abcam 
Caveolin-1 0.2 4 Santa Cruz 
Flotillin-1 0.8 8 Abcam 
ARF6 1 8 Sigma 
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3.11 Confocal laser scanning microscopy 
 The cells were investigated for colocalization between fluorescently stained traffic 
proteins and fluorescently tagged delivered siRNA. HeLaLuc cells were seeded on microscope 
cover slides that were placed inside of 6-well plates at density of 1X10
5
 cells/well and allowed to 
incubate for 48 hours. The particles were formed as described in sections 3.6 and 3.7, except the 
fluorescently labeled (AF-647) siGL3 was used. The cells were transfected with polyplexes and 
lipoplexes at final siRNA concentration of 5 nM in serum-free media for 2 hours. The particle-
containing media was aspirated and the cells were rinsed three times with PBS prior to being 
fixed with 3.7% formaldehyde in PBS for 10 minutes. When the polyplexes were delivered, the 
cells were permeabilized with 0.25% Triton X-100 in PBS solution for 10 minutes. This step was 
skipped when lipoplexes were delivered because it washed them off the slides. The well plates 
were protected from the light throughout the procedure, and the cells were incubated at room 
temperature in 10% FBS in PBS solution to prevent non-specific staining. An hour of incubation 
of cells in the primary antibody solution (Table 3.2) was carried, and the cells were again washed 
three times with PBS and incubated in 5µg/ml of secondary fluorescently labeled (AF-488) 
antibody (Invitrogen). Finally, the cells were washed trice with PBS, the cover slides were 
removed from the wells and fixed with Prolong Gold (Invitrogen) reagent that contained DAPI 
for nuclear staining. The slides were left in a dark place overnight and were sealed in the 
following day by nail polish. 
 In order to determine if the particles that entered the cells did so through 
macropinocytosys, fluorescently labeled (AF-568) 10kDa dextran (Invitrogen) was used as a 
market for the fluid phase uptake by the cells. As described above, the transfection of 
fluorescently labeled siGL3 was performed on cells cultured on the cover slides, but100 minutes 
after the transfection, the dextran was added to wells to yield final concentration of 1.5mg/ml. 
The dextran was allowed to incubate with cells for 20 minutes. The media was then aspirated and 
the wells were washed three times with PBS, fixed with 3.7% solution of formaldehyde. The 
slides were extracted from the wells and fixed with Prolong Gold Antifade reagent that contained 
DAPI similarly to when protein immunostainning was performed. The microscopy was 
performed using LSM 700 microscope (Zeiss, Oberkochen, Germany) 
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3.12 Energy dependency on uptake and RNAi 
 The investigation of the energy dependency on the endocytosis of siRNA particles was 
performed using two temperature regimes. The seeding, transfections, luciferase and uptake 
(flow cytometry) measurements were carried out the same way as described above. However, 
during the incubation post transfection procedure, one plate was placed in 4°C refrigerator while 
the other in 37°C incubator. The incubation for the uptake study was done for 2 hours, and the 
incubation for the luciferase activity study was performed for 4 hours. After the incubation, the 
cells were washed with PBS, the media was replaced with serum-containing media and the plates 
from both groups were returned back to the 37°C incubator. In order to avoid thermal shock, the 
cells that were incubated at 4°C were washed with cold (4°C) PBS, and the fresh culture media 
that was added post transfection to the wells was also cold.  
3.13 Particle sizing 
 Dynamic light scattering was used to measure the sizes and the polydispersity of the 
particles. Particles were prepared in PIPES buffer as described in X.X, except of the final siRNA 
concentration was 3 times higher than in the solution that was prepared for transfection, since 
lower concentrations of the particles were not detectable. However, the siRNA/vector weight 
ratios were preserved. The solutions were placed in transparent cuvettes, allowed to incubate at 
room temperature for 15 minutes and measured 10 times each using Brookhaven Instruments 
Corporation 90 Plus Particle Size Analyzer (Holtsville, NY). 
3.14 Calculations 
 If not otherwise stated, the experiments were performed in triplicates. Except for the 
uptake studies, siLam was used as a control group with exactly the same experimental conditions 
(drug concentrations, amount of vector used, temperature, etc.) as in siGL3 groups apart of 
different siRNAs. This accounted for the toxicity and side effects of the drugs and the materials 
that were used. Equation 1 was used to calculate knockdown of reporter protein. 
             
                                     
                                     
     (1) 
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For the flow cytometry, the average fluorescence of delivered tagged siRNA (AF-647) of each 
group was normalized to the average fluorescence of the control (not treated or not modified) 
groups. 
The error bars on graphs represent standard deviations. One-Way ANOVA with Tukey means 
comparison test in conjunction with equivalent surrogate data technique
111
 using OriginPro8.6 
(Northampton, MA) program were used to calculate statistical significance. The significance 
level (α) was set to 0.05. The star-signs above the presented data indicate statistically 
significance compared to the control group. 
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CHAPTER 4: EXPERIMENTAL RESULTS 
4.1 Selection of lipid vector composition 
 Three lipids were combined to create lipid-based siRNA vector. HeLa cells were 
transfected using lipids of various compositions in order to determine the optimal composition 
and the amount of the vector to be used. As Figure 4.1 indicates, vectors that contained large 
amounts of DOTAP (>50% of total vector weight) promoted higher knockdown than vectors 
with higher content of the helper lipids (cholesterol and DOPE). The knockdown was in the 
range of 7-25% and 30-60% when 1:1 and 10:1 (w:w) of vector:siRNA was used, respectively. 
The vector composition of 11:2:7 at 10:1 was used for the remainder of this study. 
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Figure 4.1: Lipid vectors with an array of compositions were tested. Two different amounts of vectors 
were used: A. 1:1 and B. 10:1 of vector:siRNA on the weight basis. 
 
A 
B 
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4.2 Toxicity of chemical inhibitors 
One of the most important criteria for choosing the endocytosis inhibitors is their overall 
toxicity on the investigated cells. CellTiter Blue assay was performed to determine the feasible 
range of concentrations of the drugs. All of the drugs that were used in the study showed 
significant toxicity at higher concentrations. Table 4.1 details the range of the concentrations of 
drugs along with the toxicities that were associated with this range and Figure 4.2 presents the 
complete results of the toxicity investigation. 
 
Table 4.1: List of the drugs, the concentrations used in the study and their associated toxicities 
Name of the Drug Concentration Range Used in the 
Study 
Toxicity Effects on HeLaLuc 
Cells at the Highest 
Concentration Used (expressed 
in cell viability) 
Chlorpromazine 0.5-5 µg/ml 45% 
Amantadine 80-200 µg/ml 91% 
Genistein 20-70 µg/ml 66% 
mβCD 3-10 mg/ml 92% 
Amiloride 10-50 µg/ml 69% 
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Figure 4.2: The viability of the HeLa 
cells at a wide range of five drugs that 
were used in the study. 
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Figure 4.3: The effects of the temperature during the transfection on the knockdown and uptake of particles. 
(A) The RNAi promoted by both vectors was reduced; however, the effect was more significant for PEI. (B) At 
low temperature the uptake of polyplexes almost halted and did not change for polyplexes.  
4.3 Dependency of uptake and effective RNAi on thermal conditions 
 In order to investigate the dependency on energy of the total uptake of the poly- and 
lipoplexes and effective endocytosis, transfections were performed at two different temperatures. 
If the uptake and the effective endocytosis are significantly inhibited by low temperatures, then it 
can be deduced that energy-dependent cellular machinery is involved in the process. However, if 
at lower temperatures the uptake of particles continues to occur and leads to RNAi then energy-
independent direct fusion between the particles and cellular membranes is likely to be a major 
component of the process.  
The results of the transfections with incubation at low and physiological temperatures 
indicate that RNAi mediated by both of the delivery vectors is energy dependent. Lower 
temperature reduced knockdowns that were mediated by both vectors; however, the effect was 
more dramatic in the case of the PEI vectors (Fig. 4.3. A) 
As for the uptake, lower temperature almost completely inhibited the uptake of the 
polyplexes, but the uptake of the lipoplexes was almost not affected (Fig. 4.3. B). Together these 
A B 
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results indicate that the endocytosis of the siRNA/PEI particles is highly dependent on biological 
activity of the HeLa cells while the internalization of the siRNA/lipid occurs through direct 
fusion with plasma membrane.  
4.4 Inhibition of uptake using drugs 
 Chemical inhibitors of endocytosis were used to investigate their influence on the uptake 
of the siRNA particles (Fig. 4.4). A range of concentrations was chosen based on their toxicity 
and literature values. Since multiple drugs reduced the uptake of the PEI particles, it is evident 
that the uptake of these was occurring through multiple pathways. Chlorpromazine and 
amantadine reduced the uptake of the siRNA/PEI particles at higher concentrations (>3 µg/ml 
and >150 µg/ml, respectively) indicating entrance through CME. The reduction of uptake by 
~40% when genistein and amiloride were used implicated a role of CvME and MP in the uptake 
of PEI particles. The uptake of the lipid particles was most remarkably reduced by mβCD (25 – 
60 % reduction in the drug concentration range of 3 – 10 mg/ml). This means that the cholesterol 
in the plasma membrane is important in the uptake of the lipid particles. Amantadine and 
amiloride reduced the uptake of the lipid and polymer particles (amantadine: up to 40% for 
polyplexes and 25% for lipoplexes; amiloride: up to 40% for polyplexes and none for 
lipoplexes), but these effects did not persist at higher concentrations, indicating that the effects 
might decrease due to toxicity of the drugs. The drugs might affect cells differently at higher 
concentrations. The reduction in uptake of lipoplexes (~20%) occurred only at the highest tested 
concentration of genistein (70 µg/ml), so it is not likely that CvME is implicated in uptake of 
lipoplexes, but rather a different uptake mechanism is governing this process. 
4.5 Inhibition of RNAi using drugs 
 Figure 4.5 represents the effect of the chemical inhibitors on RNAi. When PEI was used 
as a delivery reagent, the RNAi was significantly inhibited by genistein (from 35% to up to 8% 
knockdown) and amiloride (from 35% to up to 10% knockdown), indicating that even though the 
siRNA/PEI particles enter the cells through multiple pathways, those that enter through CvME 
and MP lead to RNAi. Genistein and mβCD reduced the knockdown mediated by siRNA/lipid 
particles (genistein: from 55% to up to 25% knockdown; mβCD: from 55% to less than 5% 
knockdown). This shows that CvME lead to the knockdown, and that cholesterol was also 
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essential to the process. Amiloride did not inhibit the knockdown mediated by the lipid-delivered 
siRNA at higher concentrations. This could be either due to side effects of amiloride at higher 
concentrations or due to possibly more efficient pathways that increased their activity as MP was 
inhibited. 
 Since not all the drugs showed a clear pattern of inhibition of uptake and RNAi (gradual 
decrease of uptake and RNAi as their concentration increased), this study demonstrates the 
importance of using an array of concentrations versus simply choosing a single value. Also, it is 
important to note that not every inhibition of uptake led to reduction in knockdown.  
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Figure 4.4: Normalized uptake in presence of chemical inhibitors at an array of concentrations. When PEI was 
used, all of the drugs except of mβCD reduced the uptake. When lipid was used, mβCD, genistein (at higher 
concentration) and amantadine influenced the uptake. 
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Figure 4.5: Effects of chemical inhibitors on RNAi. Neither chlorpromazine nor amantadine influenced the 
RNAi in either of the particles. Genistein reduced the knockdown in both types of particles, and mβCD 
dramatically reduced the knockdown in lipid-particles only. Amiloride at higher concentration reduced the RNAi 
mediated by PEI. 
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4.6 Uptake and RNAi efficiency of particle in RNAi-modified cells 
 HeLaLuc cells were modified to reduce their content of proteins that are implicated to be 
essential to specific endocytosis pathways using siRNA with a commercially available 
transfection reagent. The knockdowns of the traffic proteins were confirmed using Western 
blotting (Fig. 4.6). 
The uptake of the particles and the knockdown of the reporter protein in modified cells 
are presented in Figures 4.7 and 4.8, respectively. The reduction in caveolin, flotillin and ARF6 
proteins significantly reduced the uptake of the siRNA/PEI particles (by 60, 50 and 60%, 
respectively). This implies the importance of the associated pathways in uptake. As for the 
knockdown, the PEI mediated siRNA delivery was only statistically significantly reduced (to 
almost 0 from 32%) in cells with reduced ARF6. With the reduction of caveolin and flotillin the 
knockdown was also reduced (from 32 to 22 and 21%, respectively), but the effects were not 
strongly pronounced. The knockdown of caveolin increased the uptake of the siRNA/lipid 
particles by over 20%. This means that either the structure of the plasma membranes was 
changed in a way that allowed for higher uptake or perhaps pathways other than CvME increased 
their activity and facilitated higher total uptake. 
 
 
No RNA siLam siCLT siCAV 
Clathrin Staining 
Caveolin-1 Staining 
No RNA siLam siARF siFLT 
Flotillin-1 Staining 
No RNA siLam siARF siCAV 
ARF6 Staining  
siARF siFLT siLam No RNA 
Figure 4.6: Western blots that confirm the successful knockdown of the traffic proteins 
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Figure 4.7: The proteins that mediate endocytosis were selectively knocked out, and the effect on the total 
uptake of particles was investigated. The reduction in caveolin, flotillin and ARF6 reduced the siRNA/PEI 
particle uptake. The uptake of the lipid particles was enhanced when caveolin was knocked out.    
Figure 4.8: The reduction of the traffic proteins did not influence the knockdown that was mediated by the lipid 
particles. However, the reduction in ARF6 reduced the knockdown provided by siRNA/PEI particles. Caveolin 
and flotillin also influenced the knockdown by the siRNA/PEI particles, but the effect was not statistically 
significant. 
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4.7 Confocal laser scanning microscopy 
The proteins that are directly implicated in the investigated endocytosis pathways were 
immunologically stained with fluorescent antibodies after the lipid and polymer based vectors 
delivered fluorescently labeled siRNA. The co-localization between the proteins and the siRNA 
provides for direct evidence of association of specific endocytosis pathways activities. 
When delivered with PEI, siRNA strongly co-localized with caveolin and flotillin (Fig. 
4.10 and 4.11). This provides direct evidence of the importance of the associated pathways. No 
co-localization was observed between polymer-delivered siRNA and clathrin (Fig. 4.9) or ARF6 
(Fig 4.12), so these proteins did not directly participate in the uptake. No studied proteins 
showed strong co-localization signs with lipid-delivered siRNA. However, this could be due to 
experimental difficulty to visualize lipid-delivered siRNA, since significant amounts of it washed 
of the slides during the permeation and washing steps. Only a minor evidence of association 
between caveolin, flotillin and siRNA delivered by lipid was observed. 
Fluorescent dextran was co-delivered with siRNA particles to study if the latter enter the 
cells through MPE. Indeed, co-localization between dextran and polymer-delivered siRNA was 
observed (Fig. 4.13). But since no such co-localization was observed with lipid-delivered siRNA, 
it can be concluded that lipid/siRNA particles do not simply enter the HeLa cells with the 
surrounding fluid.  
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Figure 4.9 Result of the co-localization study between the PEI-delivered siRNA (represented in red) and 
fluorescently tagged clathrin (represented in green). The nucleus stained with DAPI and represented in blue. 
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Figure 4.10 Result of the co-localization study between the PEI-delivered siRNA (represented in red) and 
fluorescently tagged caveolin-1 (represented in green). The nucleus stained with DAPI and represented in blue. 
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  Figure 4.11 Result of the co-localization study between the PEI-delivered siRNA (represented in red) and 
fluorescently tagged flotillin-1 (represented in green). The nucleus stained with DAPI and represented in blue. 
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Figure 4.12 Result of the co-localization study between the PEI-delivered siRNA (represented in red) and 
fluorescently tagged ARF6 (represented in green). The nucleus stained with DAPI and represented in blue. 
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Figure 4.13 Result of the co-localization study between the PEI-delivered siRNA (represented in red) and 
fluorescently tagged dextran (represented in green). The nucleus stained with DAPI and represented in blue. 
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Figure 4.14 Result of the co-localization study between the lipid-delivered siRNA (represented in red) and 
fluorescently tagged clathrin (represented in green). The nucleus stained with DAPI and represented in blue. 
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Figure 4.15 Result of the co-localization study between the lipid-delivered siRNA (represented in red) and 
fluorescently tagged caveolin-1 (represented in green). The nucleus stained with DAPI and represented in blue. 
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Figure 4.16 Result of the co-localization study between the lipid-delivered siRNA (represented in red) and 
fluorescently tagged flotillin-1 (represented in green). The nucleus stained with DAPI and represented in blue. 
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Figure 4.17 Result of the co-localization study between the lipid-delivered siRNA (represented in red) and 
fluorescently tagged ARF6 (represented in green). The nucleus stained with DAPI and represented in blue. 
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Figure 4.18 Result of the co-localization study between the lipid-delivered siRNA (represented in red) and 
fluorescently tagged dextran (represented in green). The nucleus stained with DAPI and represented in blue. 
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4.8 Particle sizing 
 The size of the particles that are delivered to the cells can have a big influence on the way 
that these particles undergo endocytosis and their subsequent processing within the cells. 
Particles were formed in PIPES buffer as described in Sec. 3.6, and the results of the size 
measurements are presented in Table 4.2. After the extrusion, the sizes of the lipid particles were 
significantly reduced. However upon mixing with siRNA, the sizes dramatically increased. This 
means that either siRNA neutralized the negative charge of the lipid vesicles causing the vesicles 
to aggregate, or that each siRNA molecule electrostatically attached to multiple lipid particles 
and caused aggregations to form. The sizes of the siRNA/PEI particles were much smaller than 
siRNA/lipid particles but comparable in size to the lipid vesicles after the extrusion.  
 
Table 4.2: The results of the measurement of the investigated particles 
Particle Diameter (nm) Polydispersity 
Extruded Lipid 159.9±1.6 0.108±0.015 
Not Extruded Lipid 288.5±23.3 0.332±0.042 
Extruded Lipid + siRNA 468±19.0 0.401±0.019 
Not Extruded Lipid + siRNA 704.1±58.7 0.483±0.052 
PEI + siRNA 209.3±16.8 0.257±0.075 
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CHAPTER 5: DISCUSSION 
 Understanding the predominant endocytosis pathways that lead to efficient RNAi is 
imperative for future design of siRNA delivery vectors. Both the chemical and the biological 
techniques of selective inhibition of pathways of endocytosis were used to determine the uptake 
pathways that play the biggest role in siRNA delivery by PEI and lipids mixture. The 
investigation into the ability of polyplexes and lipoplexes that enter cells to mediate RNAi was 
also performed. 
5.1 Effects of temperature 
 The change in ambient temperature during the transfections is a widely used method to 
study the dependency of the uptake and activity of particles on energy-dependent biological 
activity of cells.
100,112
 Decreasing the temperature during the transfections inhibits active 
transport processes (endocytosis) that cells might use.  
 As expected, lowering the temperature to 4°C greatly decreased the uptake of the 
polyplexes into the cells. As a consequence, the RNAi mediated by the polyplexes was also 
sharply decreased. This is consistent with a common agreement that the uptake of these 
complexes occurs through endocytosis.
15,113
 On the contrary, the uptake of the lipoplexes was not 
affected by the low temperatures while RNAi mediated by lipoplexes was lower at lower 
transfection temperatures. It is likely that the reduction of knockdown mediated by the lipid 
vector was due to a reduction in the intracellular activity of the cells as a result of the low 
temperature and not due to a decreased amount of siRNA that entered the cells.  It is possible 
that at lower temperature the siRNA/lipid particles entered the cells through a mechanism that 
was different from the mechanism that leads to a successful RNAi, and this resulted in the 
reduced knockdown despite delivery of approximately equal amounts of siRNA at both 4°C and 
37°C. Our findings demonstrate that lipoplexes entered the cells through a fusion with the 
plasma membrane rather than through active endocytosis. The reduction in activity induced by 
lipoplexes at lower temperatures was in agreement with observations by other labs
100,101
, but our 
finding of the total uptake of the lipoplexes are significantly different. The discrepancy could be 
easily explained. We employed a lipid-based vector with a composition that was optimized for 
siRNA delivery, while Lu et al. used DharmaFECT1 and Lipofectamine2K was used by Ming et 
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al., so it is possible that our delivery reagent was internalized more efficiently by direct fusion 
rather than endocytosis.
100,101
 
5.2 Chemical inhibitors 
 Although the most common investigation method, chemical inhibitors are the least 
specific in selective inhibition of pathways. However, since they are routinely exploited by most 
of the researchers that study endocytosis, they are suitable for comparison with other studies and 
good as an initial method in studying endocytosis. 
 Chlorpromazine is usually used as a disruptor of CME that prevents the dissociation of 
clathrin coated pits from the plasma membrane. Chlorpromazine induced the highest toxicity in 
the investigated cell line (Table 4.1). The uptake and the subsequent RNAi of the lipoploplexes 
were not affected even by the highest concentrations of chlorpromazine. In the polyplex case, the 
uptake was gradually decreased with the increase in chlorpromazine concentration. Contrary to 
that, RNAi was induced with gradual increase of chlorpromazine concentration, albeit the 
increase was not statistically significant. This means that polyplexes entered the cells through 
CME, but this pathway did not lead to RNAi. The increase in the functional effect of the cargo at 
higher concentrations of chlorpromazine is consistent with previous findings.
103,114
 This could be 
due to increased amounts of particles that are available to clathrin-independent pathways that are 
more effective in RNAi or due to side effects of chlorpromazine. Amantadine was also used as a 
disruptor of CME by stabilization of clathrin coated pits on plasma membrane. This drug was not 
consistent in blocking the uptake of lipoplexes at higher concentrations, but it consistently 
reduced the uptake of the polyplexes. Amantadine did not significantly alter RNAi induced by 
both types of the vectors, but the RNAi was slightly reduced in the case of polyplexes. The 
results again indicate that lipoplexes did not enter the cells through CME. It appears that the 
reduction in uptake of polyplexes by amantadine was not sufficient to reduce RNAi. Overall, the 
results from these drugs indicate that there was no association between CME and lipid particles, 
but a large fraction of polymer particles entered the cells through CME without being efficient in 
mediating the knockdown. 
 Genistein was used as a CvME inhibitor by inhibiting tyrosine kinase, but can also 
interfere with dynamin recruitment to the plasma membrane which can lead to CME inhibition. 
53 
 
Both the uptake of and knockdown mediated by the polyplexes was greatly reduced in the 
presence of genistein. However, the effect on lipoplexes activity was not significantly altered by 
the same amounts of genistein. Only higher concentrations of genistein (>50 µg/ml) reduced 
RNAi mediated by lipoplexes and their total uptake. If genistein interferes with the movement of 
caveolin molecules, then it might also effect the distribution of cholesterol on plasma membrane, 
since these two are known to interact. Altering the distribution and organization of cholesterol in 
the plasma membrane can lead to alterations of direct fusion process of lipoplexes, but this point 
will have to be confirmed. Based on the genistein inhibition, CvME might be involved in uptake 
and processing of both types of the particles. 
 As described earlier, cholesterol can play a major role in multiple endocytosis pathways. 
In addition to that, the depletion of cholesterol from the plasma membrane might reduce the 
amount of cholesterol inside of the cells which will have effect on the fusion events that occur in 
intracellular space between various vesicles with lipid-based membranes. We studied the effects 
of cholesterol depletion using mβCD. As expected, this drug greatly reduced the uptake of 
cholesterol-rich lipoplexes and knockdown of reporter gene provided by lipoplexes. This might 
be a consequence of reduction of fusion events between the lipoplexes and plasma membranes. 
We observed a strong and consistent inverse correlation between the concentration of mβCD and 
uptake and activity of siRNA/lipid particles.  Interestingly, mβCD was the only drug that 
affected the lipoplexes to a higher degree than polyplexes. The endosomes that are formed as a 
result of CME are rapidly acidified, so the release of the cargo is probably relying on the “proton 
sponge” effect rather than on natural “leakiness” of endosomes as they fuse with other 
intracellular compartments. If the majority of polyplexes enter cells through CME, then it is 
expected that the subsequent RNAi process would be less dependent on cholesterol than the 
internalization of lipoplexes through direct fusion. The results obtained by our lab are consistent 
with previously published data where mβCD had higher effect on uptake of lipoplexes rather 
than on polyplexes.
101
 
  Macropinocytosis can play a major role in HeLa cells, since these are rapidly dividing 
cancer cells. Even though amiloride is considered to be a highly specific MPE inhibitor, the 
results indicate that it might have changed its mode of action at higher concentrations. The total 
uptake of lipoplexes was not affected by any concentrations of amiloride, but the uptake of 
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polyplexes was initially reduced and then increased as the concentration of amiloride increased. 
Since the decrease in the polyplex uptake was very significant, it is evident that MPE is 
important for uptake of polyplexes. Amiloride consistently decreased the RNAi by polyplexes, 
but the effect on lipoplexes was more complex: knockdown decreased first and then increased at 
the highest concentration of amiloride. It is possible that such behavior occurred as a result of a 
non-specific effect, especially since the toxicity of amiloride was fairly high in the investigated 
cell line. Just like with other chemical inhibitors, the effects might greatly vary between cell lines 
and concentrations. For example, in 2010 Alam et al. used 5µM amiloride (~1.2 µg/mL) to 
inhibit MPE in human melanoma cells
115
, however in 2011 the same group published an article 
where the concentration of 100 µM amiloride was used to inhibit MPE in HeLa S3 cells.
101
 This 
is a common occurrence and one of the reasons why we chose to investigate a wide range of 
concentrations of each inhibitor. Nevertheless, the data indicates that polyplexes are more 
affected by MPE inhibition than lipoplexes, and MPE leads to efficient knockdown in the case of 
polymer-based delivery.  
5.3 Biological inhibitors 
 RNAi was used to selectively knockdown proteins that are essential for the endocytosis 
pathways. Even though this technique does not guarantee a complete shutdown of specific 
pathways, it significantly decreases their activity in more selective manner than chemical 
inhibitors
105
. The success of knockdown was confirmed with Western blots (Fig. 4.6). 
 The knockdown of clathrin inhibited CME. Surprisingly, such inhibition did not have 
major effect on uptake or RNAi of polyplexes or lipoplexes. Inhibition of CvME by siRNA 
significantly reduced the uptake of polyplexes. This reduction in the polyplexes uptake only 
marginally reduced RNAi. The situation was very similar when FME was inhibited. This means 
that even though a significant fraction of polymer-based particles entered the cells through 
CvME and FME, they were not the major contributor to RNAi. Recent publication that includes 
investigation of endocytosis pathways of polymer-delivered DNA vectors in epithelial cells used 
a similar technique to knock down flotillin and caveolin proteins. Their results showed that the 
knockdown of caveolin can also reduce the amount of flotillin.
64
 We cannot confirm their result, 
since we used different controls in our Western blots. However, it cannot be ruled out that a 
similar situation could possibly occur in our experiments, even though we used different siRNA 
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sequences, different cell lines and slightly different procedures. Caveolin is homologous to 
flotillin, so they might have a similar effect on the organization of cholesterol in plasma 
membranes. The inhibition of CvME actually increased the uptake of lipoplexes, and this was 
not observed with FME inhibition. Since the depletion of cholesterol from plasma membrane by 
mβCD greatly reduced the uptake of lipid particles, it is suggested that caveolin changed the 
cholesterol distribution of the plasma membrane. Since caveolin is mostly located in secluded 
regions on plasma membrane (caveolae) and attracts cholesterol, we hypothesize that depletion 
of caveolin leads to more sparse distribution of cholesterol on plasma membrane which in turn 
leads to greater number of sites where the fusion between the cholesterol-rich lipoplexes and 
plasma membrane can occur. It is also probable that caveolin depletion led to easier recruitment 
of cholesterol by other pathways (such as FME) which mediated significant increase in the 
uptake. However, these claims will have to be experimentally verified. Since the knockdown of 
other traffic proteins did not significantly alter the uptake or the processing of the lipoplexes, we 
conclude, in agreement with other groups
100,101
 , that oligonucleotide/lipid particles are likely to 
directly fuse with plasma membrane rather than undergo endocytic process.  
The knockdown of ARF6 significantly reduced the uptake of the polyplexes, but the 
effect on the RNAi was the most dramatic. Since ARF6 protein is involved in multiple pathways, 
it is impossible to conclude from these data which pathway was inhibited. There are indications 
that ARF6 is involved in fluid-phase uptake pathways
64
, MPE and FME might be involved in the 
uptake of the polyplexes. This result can be supported by the experiment with inhibition using 
amiloride. ARF6 inhibition certainly also directly reduced the activity of the ARF6-dependent 
pathway. Since ARF6 is heavily involved with recycling pathways, we hypothesize that 
reduction in ARF6 expression decreased the number of events in which fusion and budding of 
endocytic membranes occurred. Since these events can cause “leakiness” and escape of the cargo 
to the cytosol, their reduction will lead to fewer polyplexes that escaped from endosomes. This 
might be the primary reason for such a drastic decrease in RNAi with a decrease in the uptake 
that was comparable to decrease in other groups. Since the uptake was measured 2 hours post 
transfection, it is also possible that the reduction in the recycling mechanism did not dramatically 
influence the uptake, but the RNAi that was evaluated 20 hours after the 4 hours transfection was 
affected as a result of some unknown biological responses.  
56 
 
 
5.4 Microscopy 
 Confocal microscopy observation of co-localization between the traffic proteins and 
delivered siRNA is one of the most direct methods of studying endocytic routes. Strong co-
localization might be a false-positive, since the stained proteins might be moving from the site of 
their production to the plasma membrane or be involved in various retrograde trafficking without 
being directly involved in the investigated endocytosis pathway. As described in the background 
chapter, proteins that are mainly involved in one pathway might be present in vesicles that are 
formed in other pathways and lead to false-positive result. However, if no co-localization is 
observed, then the conclusion about the importance of specific pathways in the uptake can be 
reached with higher confidence. It is worthy to note that co-localization cannot directly show the 
impact of pathways on RNAi, but if it is observed that many particles are taken up by a specific 
pathway, and this pathway does not lead to RNAi, then an appropriate recommendation can be 
made about the future utility of this pathway in the design of novel delivery vectors. 
 Strong co-localization was observed between the siRNA delivered by the polyplexes and 
caveolin, flotillin and fluid phase marker dextran. ARF6 and clathrin did not co-localize with 
siRNA. This means that ARF6 was probably acting as a regulator of the polyplexes uptake rather 
than being directly involved in the process. The lack of co-localization with clathrin was 
surprising in light of the results of the total uptake that were obtained with CME inhibition by 
chlorpromazine and amantadine. However, all other experiments confirm that CME is not 
involved in endocytosis of polyplexes. The co-localization with other proteins confirms that 
polyplexes enter the HeLa cells through multiple pathways with CvME being the most effective 
in leading to RNAi.  
 Punctate patterns of fluorescent siRNA could be enough to suggest that particles localize 
in endolysosomes
100
 or at least in some intracellular vesicles. The lack of aggregations and 
accumulation of fluorescently labeled siRNA inside of cells suggest that no uptake of particles 
occurred, the particles could be washed off during the staining process or the distribution of the 
siRNA in the intracellular space is sparse. This is because single fluorescent molecules provide 
much weaker fluorescence signals than aggregates of such molecules, and these weak signals are 
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usually filtered out. In the experiments presented here, we could not obtain punctate patterns of 
siRNA molecules when they were delivered by lipid vector and stained in the same manner as 
the cells transfected with polyplexes. The method used for staining in this study mostly followed 
the procedure designed for polyplexes
102
, but poor immobilization on the slides of the polyplexes 
could still be happening as a result of unique composition of the employed lipid vectors. In order 
to get more meaningful results, the modification of the staining procedure was done to make it 
“more gentle” by eliminating the permeation step. This yielded higher retention of lipid-based 
particles on the slides. However, this also limited the access of the primary and secondary 
antibodies into the cells. Nevertheless, no co-localization between any of the fluorescent proteins 
and lipid-delivered siRNAs was observed. In addition, fewer punctate aggregations of siRNA 
were detected with lipid than with polymer based vectors, even though higher knockdown was 
observed with lipoplexes compared to polyplexes (control groups in Fig. 4.3). This implies that 
not only did lipids not deliver siRNA through one of the known mechanisms investigated here, 
but this new mechanism allowed for more efficient and perhaps more rapid release of siRNA 
from the particles than in the case of the polyplexes. 
5.5 Size influence 
 Size of the particles can have a profound effect on the endocytosis route that the particles 
undergo. Experiments with internalization of latex particles of various sizes into murine 
melanoma cells revealed that particles up to 200 nm in size enter the cells through CME, while 
particles in the range of 200 to 500 nm entered the cells through a pathway that is associated with 
caveolin protein and heavily dependent on cholesterol. However, even the entrance of small 50 
nm latex particles was severely reduced by ~50% as a result of cholesterol depletion.
116
 The 
polyplexes that were investigated in our study were approximately 200 nm in diameter. The 
chemical properties of PEI particles bound to siRNA and lipoplexes are expected to differ from 
simple latex particles, and different cell line was used in our study. Still, our data indicate that 
even 200 nm polyplexes are not likely to enter the cells through CME. The lipoplexes used in 
this study were approximately 450 nm in diameter. This is much larger than the limit of the 
particles that can internalize through CME but not completely outside of the range of particles 
that enter through endocytosis. It is apparent that the rigid structure of clathrin-coated pits limit 
the size of the internalized particles more than coats of vesicles originated from other 
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pathways.
116
 All together, this supports our hypothesis that the polyplexes in our experiments 
entered the cells through various routes other than CME. It was also reported that the 
internalization of larger particles depends on cholesterol much more than the internalization of 
smaller particles.
116
 The results obtained in our experiments confirm this observation, even 
though we hypothesize that lipoplexes carrying siRNA mostly fuse with the plasma membranes 
unlike the latex particles that lack this function. Cholesterol in plasma membrane is necessary for 
localization of various proteins, actin reorganization and membrane ruffling.
52
 It is difficult to 
determine which of these functions is the most important for the uptake and processing of 
particles, but it is highly likely that it is a combination of these functions. 
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CHAPTER 6: CONCLUSION AND FUTURE DIRECTIONS 
 An extensive investigation of the predominant endocytosis pathways that are employed 
by HeLa cells to internalize and process siRNA-based polyplexes and lipoplexes was performed. 
Temperature variation during the transfection step was used to determine the energy dependency 
of the uptake of particles. The effects of chemical inhibitors and selective protein knockdown on 
uptake and RNAi of poly- and lipoplexes were investigated using flow cytometry and reporter 
gene knockdown. Confocal fluoresce imaging was carried out to investigate co-localization 
between the proteins that are directly participating in endocytosis pathways and delivered 
siRNA.  
 Lowering the temperature during the transfection greatly reduced the uptake of 
polyplexes and did not affect the uptake of lipoplexes. RNAi mediated by polyplexes almost 
completely halted while lipoplexes still provided considerable knockdown. This means that 
polyplexes use energy-dependent endocytosis while lipoplexes mostly directly fused with 
membranes delivering siRNA. Chemical inhibitors, albeit not very specific, revealed that 
polyplexes enter the cells through CME, CvME and MPE, but CvME and MPE allow for more 
efficient RNAi than CME. The uptake of lipoplexes is highly dependent on cholesterol; some of 
the lipoplexes might enter cells and mediate RNAi through CvME. A more specific technique of 
selective pathway shutdown demonstrated that CME is not involved in uptake and processing of 
polyplexes, and this was also confirmed by microscopy. The same techniques showed that 
uptake of polyplexes occurs through multiple pathways that include CvME, FME, MPE, and 
somewhat depends on ARF6. All of these pathways are also functional in RNAi, and ARF6 is 
crucial for efficient processing of polyplexes. The effect of the knockdown of traffic proteins 
showed that only the reduction in caveolin-1 in plasma membrane can affect the uptake of 
lipoplexes, but this does not lead to a significant change in the mediated RNAi. Oligonucleotides 
delivered by lipids did not co-localize with any of the stained proteins, and it appears that less 
accumulation in intracellular compartments of siRNA delivered by lipids occurred compared to 
polymer-delivered system. 
 The results of this study suggest that for design of siRNA vectors more attention should 
be given to release of the polymeric particles from endosomes, but they should not be based on 
the acidification of CME-originated endosomes but rather on disruption of endosomal 
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membranes by other means. Perhaps the polymer that specifically evades CME can be designed 
by chemical modifications of conjugations with various ligands. Lipids are more promising 
vectors, since they allow for release of siRNA directly into the cytosol and evade limitations of 
intracellular trafficking. However, lipids without any additional modifications might deliver the 
cargo into the cells too rapidly in the case of systemic (intravenous) delivery. Efficient lipid 
vectors are likely to deliver their cargo close to the location of administration, and since they 
distribute their cargo inside of the cells in an efficient manner (with no accumulation in separate 
endolysosomal compartments), the chance that they will exocytose the particles back and allow 
for their continued circulation is much slimmer than in the case of polymer delivery systems.  
 The mechanism of endocytosis has not been completely interpreted. Not only are the 
steps of some of the pathways unknown, but it is likely that there are some pathways that have 
not been discovered yet. The design of the vectors for gene delivery will heavily depend on the 
biology of endocytosis. As a result, the future studies should concentrate on the kinetics of the 
process rather than solely on the biology. It is highly important to determine the limiting steps of 
the gene delivery. Perhaps, this will also have to be done through multiple techniques such as co-
localization with Förster resonance energy transfer and more specific flow cytometry assays. The 
data from such experiments will have to be quantified from the studies of multiple vectors, and 
clear conclusions will be done to connect the structure and the materials of these vectors with 
their delivery efficiency and limiting steps. 
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